Eyeworld

42 | EYEWORLD | DECEMBER 2022 ATARACT C References 1. Kim SJ, et al. Topical nonste- roidal anti-inflammatory drugs and cataract surgery: A report by the American Academy of Ophthalmology. Ophthalmolo- gy. 2015;122:2159–2168. 2. Hoffman RS, et al. Cataract surgery and nonsteroidal an- ti-inflammatory drugs. J Cataract Refract Surg. 2016;42:1368–1379. 3. Shorstein NH, et al. Compar- ative effectiveness of three pro- phylactic strategies to prevent clinical macular edema after phacoemulsification surgery. Ophthalmology. 2015;122:2450– 2456. Relevant disclosures Hoffman: None Shorstein: None Contact Hoffman: rshoffman@finemd.com Shorstein: nshorstein@seva.org The biggest impediment for the use of many of these products is the expense. "Older NSAIDs, which are usually not as effective as the latest NSAID products, are less expensive for patients. I tend to stick to these older NSAIDs due to complaints from patients regarding the cost of acquiring the latest and greatest product," Dr. Hoffman said, noting that he most frequently uses generic prednisolone acetate and generic ketorolac or bromfenac in his topical regimen. "As these newer NSAIDs become cheaper gener- ics, I tend to switch to them." Dr. Shorstein said his anti-inflammatory reg- imen changed in 2008 when he switched from topical prednisolone to subconjunctival triam- cinolone injection. "This change occurred about 6 months after I began injecting intracameral antibiotic without topical postop antibiotic drops for endophthal- mitis prophylaxis. I was comfortable injecting subconjunctival steroid, as I had experience do- ing this in patients with poorly controlled iritis, and there were a few studies in the literature showing the safety and effectiveness of subcon- junctival steroid injections at the end of cataract surgery to reduce inflammation," he said. Dr. Shorstein said that when he was in prac- tice at Kaiser Permanente (he retired from prac- tice and is now doing research), a retrospective cohort study found reduced risk of macular edema in eyes with a combination topical drop (steroid plus NSAID) compared to steroid alone or injection of 2 mg of triamcinolone (the inci- dence among these latter two was similar). 3 "Some surgeons surmise that the effect of reduced inflammation seen with combination treatment (steroid plus NSAID) in a number of studies comparing it to steroid alone is due to an overall increase (usually a doubling) in the total dosage of anti-inflammatory drug in the combination group," Dr. Shorstein said. "Our group subsequently increased the dosage of triamcinolone to 4 mg, injecting a few more millimeters inferior from the limbus to reduce the risk of intraocular pressure spike, and we noticed even fewer patients with macular ede- ma, akin to the combination group. We have not published these results as of yet." When asked whether NSAIDs should be used in every case or in specific, higher-risk cases, Dr. Hoffman said that he doesn't think ei- ther stance is wrong. NSAIDS, he explained, are primarily used to reduce the incidence of postop cystoid macular edema (CME), and they offer some pain relief and can help maintain pupil dilation intraoperatively. The overall incidence of CME after cataract surgery is 1–2%, which means that 98% of patients could be using an NSAID somewhat unnecessarily, Dr. Hoffman said. Diabetic patients are more likely to de- velop CME, so Dr. Hoffman said he'll order the strongest NSAIDs for these patients. While Dr. Shorstein said his practice had been to inject steroid as the sole anti-inflam- matory agent in routine patients, if patients have a history of diabetic macular edema, vein occlusion, uveitis in the operated eye, or postop macular edema in the fellow eye, he would prescribe postop diclofenac or ketorolac for 2 weeks. He also said he might add a topical NSAID to a topical steroid for younger patients (in general, he avoids injecting triamcinolone in patients younger than 50 and in high my- opes) because they may exhibit a more vigorous inflammatory response. "In my opinion, NSAIDs are a reasonable postop regimen," Dr. Shorstein said. "The optimal treatment period, whether to begin a few days preop or not and for how long to treat after surgery (2 weeks, 4 weeks, or 6 weeks) has not been completely worked out yet. Most generic NSAIDs seem to be as effective as newer brands, however, the newer products have been approved for fewer dose instillations per day, which may increase patient adherence." The 2016 ASCRS Cataract Clinical Com- mittee paper stated that "Both universal and selective approaches to incorporating NSAIDs have validity, and neither should be considered a standard of care in modern cataract surgery." NSAIDs do carry a risk for adverse effects, namely punctate keratopathy, according to Dr. Hoffman. "Despite this, I currently prescribe NSAIDs and steroids for all of my cataract patients, however, if they show signs of significant epithe- liopathy on the first postoperative day (especial- ly in dry eye patients), I will stop the NSAIDs but continue the topical steroids," he said. He added that he might hold off on NSAIDs altogether in patients with severe dry eye. On the flip side, there are patients who are steroid responders. Dr. Hoffman said these patients might have their steroid discontinued after a week but continue on a strong NSAID until the anterior chamber is quiet. continued from page 40

• Blank Page
• Blank Page (1)